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Abstract
Background: Chronic rhinosinusitis (CRS) is a common disorder associated with other respiratory tract diseases
such as asthma and inhalant allergy. However, the prevalence of these co-morbidities varies considerably in the
existing medical literature and by phenotype of CRS studied. The study objective was to identify the prevalence
of asthma, inhalant allergy and aspirin sensitivity in CRS patients referred to secondary care and establish any
differences between CRS phenotypes.
Methods: All participants were diagnosed in secondary care according to international guidelines and invited
to complete a questionnaire including details of co-morbidities and allergies. Data were analysed for differences
between controls and CRS participants and between phenotypes using chi-squared tests.
Results: The final analysis included 1470 study participants: 221 controls, 553 CRS without nasal polyps (CRSsNPs),
651 CRS with nasal polyps (CRSwNPs) and 45 allergic fungal rhinosinusitis (AFRS). The prevalence of asthma was
9.95, 21.16, 46.9 and 73.3% respectively. The prevalence of self-reported confirmed inhalant allergy was 13.1, 20.3,
31.0 and 33.3% respectively; house dust mite allergy was significantly higher in CRSwNPs (16%) compared to CRSsNPs
(9%, p < 0.001). The prevalence of self- reported aspirin sensitivity was 2.26, 3.25, 9.61 and 40% respectively. The odds
ratio for aspirin sensitivity amongst those with AFRS was 28.8 (CIs 9.9, 83.8) p < 0.001.
Conclusions: The prevalence of asthma and allergy in CRS varies by phenoytype, with CRSwNPs and AFRS having a
stronger association with both. Aspirin sensitivity has a highly significant association with AFRS. All of these
comorbidities are significantly more prevalent than in non-CRS controls and strengthen the need for a more
individualised approach to the combined airway.
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Background
Chronic rhinosinusitis (CRS) is the term used to denote a
common symptom set lasting for more than 12 weeks and
requires endoscopic or radiological confirmation [1]. Such
symptoms include nasal blockage, rhinorrhoea, facial pain
and loss of sense of smell. CRS affects a significant pro-
portion of the adult population with a recent European
study suggesting a prevalence of 11% [2]. The pathophysi-
ology for CRS is not yet fully understood but it is currently
accepted to roughly divide cases into two common pheno-
types – those with polyps and those without nasal polyps
(CRSwNPs and CRSsNPs respectively). There are many
proposed aetiological factors; viruses, bacteria and fungi
alongside host and environmental factors have all been
implicated with the likelihood of an array of underlying
endotypes.
Allergic fungal rhinosinusitis (AFRS) is an increasingly
recognised distinct subtype of CRSwNPs that represents a
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therapeutically more challenging condition. AFRS was
first described in 1976 [3] where resected nasal mucosa
from group of young adults with a history of asthma and
chronic nasal polyps was found to contain similar histo-
logical features, including a distinct mucinous material
containing eosinophils, Charcot-Leyden crystals, and fun-
gal hyphae. The most commonly used classification today
is that defined by Bent and Kuhn in 1994 [4] which states
that AFRS is a condition associated with five major diag-
nostic criteria; 1) evidence of type I hypersensitivity (IgE
mediated), 2) nasal polyposis, 3) characteristic computed
tomography findings, 4) eosinophilic mucus, and 5) posi-
tive fungal smear, and six associated supporting criteria; 1)
asthma, 2) unilateral predominance, 3) radiographic bone
erosion, 4) fungal culture, 5) Charcot-Leyden crystals, and
6) serum eosinophilia.
In addition to the potential causative factors already
described, aspirin is also known to exacerbate nasal
symptoms. In some patients, this is as part of aspirin ex-
acerbated respiratory disease (AERD) [5]. This was first
described in 1922 by Widal [6] as a triad of symptoms
including aspirin sensitivity, asthma, and nasal polyposis,
more commonly known as Samter’s triad [7]. AERD ini-
tially includes upper airway symptoms such as nasal ob-
struction/congestion and rhinorrhoea, and progresses
over months and years to development of lower airway
symptoms, including shortness of breath, which can de-
velop into life-threatening asthma [8].
The role of atopy in CRS is widely debated in the med-
ical literature but it is generally accepted that it is not a de-
finitive aetiological factor. The reports of the prevalence of
allergic rhinitis in CRS vary wildly, ranging from as low as
10% to as high as 84% [9–13], with differing phenotype
cases included in the relevant studies likely to be an influ-
ential factor. The European Position Paper on Rhinosinusi-
tis and Nasal Polyps suggests that a selection bias in these
studies by physicians with an interest in allergy, has led to
artificially high reporting of inhalant allergy in CRS [1].
The prevalence of asthma in CRS also varies consider-
ably in the literature, ranging from 4 to 44% [14–21], in-
fluenced by study design and phenotypes. The association
between the two conditions is commonly recognised [22]
and although the interaction is yet to be fully understood
[23], recent early biomarker research suggests that higher
serum periostin levels may denote cases of CRSwNPs with
comorbid asthma [24]. It is certainly clear that both sever-
ity and duration of CRS are associated with increasing
levels of comorbid asthma [25], suggesting poor control of
CRS heralds more lower respiratory tract disease.
The overarching aims of the Chronic Rhinosinusitis
Epidemiology Study (CRES) were to identify differences
in socio-economic variables, medical co-morbidities and
environmental exposures between patients with CRS
and healthy controls. The aim of this specific analysis
was to identify the prevalence of asthma, inhalant allergy
and aspirin sensitivity in CRS patients referred to sec-
ondary care, and to establish any differences between
CRS phenotypes and compared to control subjects with-
out CRS. This data will help to inform NHS policy
makers and clinical commissioning groups regarding
their approach to upper and lower airway disease.
Methods
The CRES was approved by the Oxford C Research Eth-
ics Committee (Ref: 07/H0606/100), sponsored by the
University of East Anglia (UEA) and funded by the An-
thony Long and Bernice Bibby Trusts. Details of the full
methods used for the whole study can be seen in the
overview publication [26].
Study design
The study was conducted between October 2007 and Sep-
tember 2013 as a prospective case-control multi-centre
questionnaire study. Following inclusion on the national
research network portfolio (NIHR CRN) in 2012, study re-
cruitment increased to an average of 100 participants per
month with a recruitment rate of 66%. The study specific
questionnaire was anonymous and therefore no consent
was required, but implied through participation. Participant
information leaflets were provided. Questionnaires were ei-
ther completed before leaving the clinic or taken home and
returned by post in prepaid envelopes. The returned ques-
tionnaires were then scanned into a database electronically,
and the electronic records were then checked by two mem-
bers of the research team for accurate correlation with the
paper questionnaires and for missing data. The question-
naire was completed on one occasion only.
Setting
A total of 30 secondary/tertiary care sites widely spread
across the UK including the devolved nations of Wales
and Scotland participated in the study where general
otorhinolaryngology or subspecialist rhinology clinics
managed patients referred from primary care.
Participants
Patients were recruited at the point of contact during
outpatient consultation in secondary care, regardless of
prior management in either primary or secondary care
and regardless of prior surgical intervention. They were
classified by sub group of CRS (CRSsNPs, CRSwNPs or
AFRS) by a clinician on the basis of their history and
endoscopic and/or CT findings, prior to completion of
the questionnaire. Controls who had no diagnosis of
nasal or sinus conditions were recruited from amongst
hospital staff and also family and friends of those attend-
ing ENT outpatient clinics (regardless of cause), pro-
vided they met the criteria below.
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Inclusion criteria
Criteria for diagnosis of chronic rhinosinusitis (CRS)
with or without polyps (EPOS guidelines) [1]:
Symptoms must be present for at least 12 weeks and
include:
 nasal blockage/obstruction/congestion and/or nasal
discharge (anterior/posterior nasal drip)
 and either facial pain/pressure and/or reduction or
loss of sense of smell
and additionally:
 endoscopic signs of: polyps and/or mucopurulent
discharge primarily from middle meatus and/or;
oedema/mucosal obstruction primarily in middle
meatus
 and/or CT changes: mucosal changes within the
ostiomeatal complex and/or sinuses
Patients classified as AFRS adhered to either the Bent
and Kuhn criteria (see above) or the modified Vancouver
criteria [27].
Exclusion criteria
 Patients unable to comprehend written English.
 Patients under the age of 18 years.
Exclusion criteria for the control group
 Active sinonasal disease - e.g. ARS, CRS, rhinitis
 Medical co-morbidity being actively treated
 Hospitalisation within the last 12 months
Variables and data sources
The study questionnaire included various specific ques-
tions for allergy and asthma as follows:
“Do you have any known confirmed allergies (on a skin
prick or blood test) e.g house dust mite? Yes/No” followed
by a free text box asking participants to state any allergies.
“Do you have any suspected allergies? Yes/No”, also
followed by a free text box.
“Have you ever experienced any allergy symptoms such
as wheezing, runny nose or itchy skin when taking as-
pirin? Yes/No”.
And under the topic of medical comorbidities, “Do you
have any of the following medical problems?: Asthma…”.
Participants did not separately undergo skin prick tests
or RAST inhalant screens as part of the study.
Bias
All of the comorbid conditions assessed were based on
self-reporting but the questionnaire design and subsequent
analysis was such that the impact of this has been mini-
mized and will be equal across all groups. Aspirin sensitiv-
ity was determined by asking specifically about responses
to aspirin that affect respiratory mucosa, such as wheezing
and rhinorrhoea, so that those with only gastrointestinal
intolerance should not define themselves as aspirin allergic
for the purposes of this questionnaire. NSAID (non-steroi-
dal anti-inflammatory drug) allergy was not specifically
enquired about but a free text box was included for any
additional allergies. Both asthma diagnosis and aspirin
sensitivity are therefore self-reported, but the former was
additionally correlated with reported asthma medication.
Sample size calculation
The sample size calculation was based on the primary
outcome of the study which was to look for common as-
sociations between socioeconomic factors and CRS. For
socio−economic scores, the standard approach is to
compare the proportion of subjects in the lower social
classes to everyone else. In order for the study to have
80% power to detect a difference of 10% in “low social
class” between controls and CRS patients, assuming a
30% rate in the CRS patients, with approximately 5 CRS
patients to 1 control patient, 965 CRS patients and 193
controls were required [26].
Statistical analysis
For the purposes of these analyses we have used descrip-
tive statistics to describe the sample; differences in the
rates of asthma, aspirin sensitivity and inhalant allergy
between groups were assessed by Chi-Squared tests. For
the analysis of aspirin sensitivity, in order to account for
the potential confounding effects, logistic regression was
also used, firstly, we adjusted the analysis for aspirin sen-
sitivity and secondly we adjusted for asthma diagnosis,
age and gender.
Results
Participant flow and missing data
Participants with allergies that were self-reported as hav-
ing been previously confirmed by skin prick test or
RAST, and those reporting suspected allergies were in-
cluded in this analysis. Figure 1 shows the details includ-
ing 21 participants who did not complete the free text
box.
Descriptive data
A total of 1470 participants’ questionnaires were available
for analysis; 1249 with CRS (CRSsNP 553, CRSwNP 651,
AFRS 45) and 221 controls. The age range was 17–
102 years (mean 52) with 54% reported as male (Table 1).
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Main results
Asthma
Those with CRS were more likely to suffer from
asthma, with those with nasal polyp subtypes even
more likely to report asthma including the majority
of those with AFRS (see Table 1). Prevalence of
asthma ranged from 21% in CRSsNPs through 47% in
CRSwNPs to 73% in AFRS. Those with self-reported
confirmed inhalant allergy and asthma (“allergic asth-
matics”) are detailed below.
Aspirin sensitivity
Those with CRS were more likely to report aspirin sensi-
tivity. In a similar manner to asthma, those with nasal
polyp subtypes were increasingly likely to report aspirin
sensitivity (AFRS more so than CRSwNPs); odds ratio
28.8 (CIs 9.89–83.8). The odds ratio for aspirin sensitivity
after adjustment for asthma diagnosis showed that only
those with AFRS were significantly more likely to report
aspirin sensitivity (OR 9.64, p < 0.001). There was no sig-
nificant interaction between CRS type and asthma on the
odds of aspirin sensitivity; this indicates that aspirin sensi-
tivity status is influenced by both asthma diagnosis and
CRS group independently. There were no significant dif-
ferences between males and females (Table 2).
Inhalant allergy
Patients with CRS were also significantly more likely to
report having a confirmed inhalant allergy (via skin prick
test (SPT) or RAST) than controls. Once again the pat-
tern mirrored that for asthma and aspirin sensitivity
above, with 1 in 5 CRSsNPs and 1 in 3 CRSwNPs/AFRS
cases reporting inhalant allergies (p < 0.02, Table 3). The
most commonly reported confirmed inhalant allergy was
house dust mite followed by grass pollen (Table 4, Fig. 2).
The prevalence of house dust mite allergy was
Fig. 1 Participant Flow
Table 1 Demographics of the participants
Controls CRSsNPs CRSwNPs AFRS
Participants 221 553 651 45
Females (%) 143 (68.4%) 259 (53.1%) 185 (32.2%) 19 (43.2%)
Mean Age (SD) 47.3 (14.9) 51.8 (15.3) 56.0 (14.6) 56.1 (12.7)
Age Range 19–82 18–84 17–102 20–76
Asthma (%) 22 (9.95) 117 (21.16) 303(46.90) 33 (73.33)
Aspirin Sensitivity (%) 5 (2.26) 18 (3.25) 62 (9.61) 18 (40.0)
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significantly higher in the CRSwNPs group compared to
the CRSsNPs group (p < 0.001). Furthermore 356 partici-
pants reported suspected allergy (i.e. not confirmed by
SPT/RAST) of which 228 reported sensitivity to inhalant
allergens (207 with CRS, 21 controls). Asthmatics with
self-reported “confirmed” inhalant allergy (Table 5) are
proportionally consistent across the groups but viewed
as a percentage of each group are seen to be most preva-
lent in the CRSwNPs and AFRS groups at 20 and 29%
respectively; odds ratios expressed for “allergic asth-
matics” were 6.71 and 10.82 within the CRSwNPs and
AFRS groups respectively.
Discussion
Key results
Our study has shown a significantly higher prevalence of
asthma, inhalant allergy and aspirin sensitivity within
the phenotypes of CRS where nasal polyps are present.
This reflects the substantial interaction between the
lower and upper airways and in particular between the
underlying aetiological mechanisms of airways path-
ology. Similar interaction is also found in those with al-
lergic rhinitis, and has been extensively reported by the
ARIA (Allergic Rhinitis and its Impact on Asthma) Task-
force [28]. Those in the AFRS subgroup have a very high
prevalence of both asthma and aspirin sensitivity that
could indicate an overlap between AFRS and what may
be AERD. The prevalence of allergy within this large na-
tional sample of CRS patients at 26% of all CRS cases is
towards the lower end of the range of allergy reported in
the literature as mentioned above, lending weight to
allergy as an associative factor in CRS rather than an
aetiological factor.
Strengths and limitations
The study is a large cross-sectional study including a
varied population from across the United Kingdom. It is
the largest epidemiological study of CRS in the UK to
date. In contrast to other epidemiological studies in
CRS, patients recruited were diagnosed by an otorhino-
laryngologist in keeping with international guidelines.
According to Asthma UK, the prevalence of asthma in
adults in the UK is 1 in 12 or 8.3%, a similar number to
our control population.
A weakness of the study is that, with the exception of
the diagnosis of CRS, it relies on participants’ self-reported
information, rather than actual skin prick test/RAST re-
sults or an aspirin provocation test. However, the ques-
tionnaire was worded to be as explicit as possible so that
participants were likely to pick the most accurate option,
for example, the question regarding aspirin allergy is
phrased so as to identify respiratory and nasal-type allergy
symptoms rather than gastrointestinal disturbances. Any
potential error in self-reporting or recall should be equal
across CRS groups so should not bias the results as far as
comparison between subgroups. It is not intended that
these results be used as a prevalence study for either con-
dition amongst the general population, but they can show
prevalence of both aspirin allergy and asthma in a large
cohort of CRS patients. Additionally, controls had no
self-reported nasal symptoms but did not undergo nasal
examination. Similarly, the reporting of confirmed
Table 2 Odds ratio of aspirin sensitivity by diagnosis, unadjusted and adjusted analysis
Factor Total
number
Asthma (%) Frequency of Aspirin
Sensitivity (%)
Odds Ratio
(OR)(95% CI)
p-value Adjusted
OR (95%CI)a
p-value Adjusted+ 2
OR (95%CI)b
p-value
for OR
Group Control 221 22 (9.95) 5 (2.26) 1 1 1
CRSsNP 553 117 (21.16) 18 (3.25) 1.45 (0.53, 3.96) 0.465 1.03 (0.37, 2.88) 0.948 1.08 (0.34,3.4)2 0.893
CRSwNP 651 303 (46.90) 62 (9.61) 4.59 (1.82, 11.58) < 0.001 2.00 (0.76, 5.25) 0.158 2.39 (0.80,7.18) 0.120
AFRS 45 33 (73.33) 18 (40.0) 28.8 (9.89, 83.8) < 0.001 9.61 (3.12, 29.63) < 0.001 12.20 (3.49,42.68) < 0.001
Asthma No 968 21 (2.12)
Yes 392 82 (17.3) 9.64 (5.89,15.79) < 0.001
aAdjusted for asthma diagnosis
bAdjusted for asthma diagnosis, age and gender
Table 3 Inhalant allergy by subgroup (vs control)
Frequency of confirmed
inhalant allergy
% Percentage difference
compared to controls
Odds ratio (vs control) 95%
Confidence interval
p-value
Control 29 13.1 1 N/A N/A
CRSsNPs 113 20.3 7.2 1.70 (1.09,2.64) 0.019
CRSwNPs 203 31.0 17.9 3.03 (1.98,4.63) < 0.001
AFRS 15 33.3 19.9 3.31 (1.59,6.89) 0.001
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inhalant allergy testing is also prone to recall bias but
again this is likely to be equal across all of the groups
compared.
Despite clear criteria for the diagnosis of AFRS, some pa-
tients with nasal polyps who have AERD could have been
erroneously categorised in the AFRS group rather than the
CRSwNPs group by clinicians. Conversely, diagnosis of
AFRS requires vigilance and careful investigation by clini-
cians, but is also limited by local laboratory facilities, so in
this multicentre study it is likely that some patients in the
CRSwNPs category will in fact have undiagnosed AFRS.
Consequently, the association between AFRS and aspirin
sensitivity/asthma may be even stronger than has so far
been described. Another caveat is that RAST results do re-
quire clinical correlation too [29].
Interpretation
CRS is known to be a complex spectrum of disease associ-
ated with respiratory co-morbidities. Basic phenotypes are
currently recognised and we have shown their differing as-
sociations with asthma and allergies; such phenotypes are
likely to be refined over time with new definitions that
may reflect these results and include the presence or ab-
sence of concomitant allergy or allergic response. Evidence
shows that the actual rate of aspirin sensitivity is higher
than the patient-reported rate [30]. Had we been able to
Table 4 Confirmed and suspected inhalant allergens
Grass HDM Cat Dog Horse Fungus/
mould
Other
pollens
Other
inhalants
Number of participants
with inhalant allergies
1 Self-reported RAST/SPT
confirmed allergies
Control 6 6 5 1 2 4 5 0 16
CRSsNPs 48 48 27 15 3 4 13 1 93
CRSwNPs 67 101 50 30 7 14 26 16 177
AFRS 6 6 5 4 1 3 0 1 13
2 Suspected allergies Control 4 4 7 1 1 2 4 0 21
CRSsNPs 18 22 7 4 1 7 29 3 95
CRSwNPs 15 28 12 5 0 6 26 2 106
AFRS 1 2 0 0 0 2 1 0 6
3 Combined confirmed and
suspected allergies
Control 10 10 12 2 3 6 9 0 37
CRSsNPs 66 70 34 19 4 11 42 4 188
CRSwNPs 82 129 62 35 7 20 52 18 283
AFRS 7 8 5 4 1 5 1 1 19
Chi-Squared test (or Fisher exact)
p-value
1 0.395 < 0.001 0.063 0.115 0.358 0.073 1 0.002
2 0.407 0.893 0.569 1 n/a 0.767 0.37 0.855
3 0.795 0.001 0.041 0.138 0.737 0.37 0.884 0.016
Fig. 2 Frequency of confirmed inhalant allergy in CRS participants
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provide an aspirin provocation test for this cohort, then
the study by Szczeklik et al. suggests we would have dis-
covered an additional 15% of cases who were unaware of
this sensitivity.
Those with AFRS were most likely to report sensitivity
to aspirin. In AERD, the pathophysiology includes changes
in the metabolism of arachidonic acid, release of inflamma-
tory mediators and cytokines, and involvement of microor-
ganisms including bacteria and viruses [31]. Abnormal
metabolism of arachidonic acid is characterized by an im-
balance between cyclooxygenase (COX) and lipoxygenase
pathways that results in an overactive lipoxygenase path-
way. This is accentuated with aspirin and non-steroidal
drug ingestion in susceptible patients, leading to increased
production of leukotrienes and intensification of airway in-
flammation. A similar inflammatory mechanism might ex-
plain the increased sensitivity to aspirin experienced by
those with AFRS. Elevated release of inflammatory media-
tors, such as histamine, have also been found to be elevated
in those suffering from CRSwNPs and aspirin The majority
of patients with AERD are thought to develop nasal polyps
during the course of their disease [31]. Their polyposis
tends to be more extensive and difficult to treat medically,
as well as presenting with higher recurrence rates after sur-
gery, in a similar manner to those with AFRS [8], therefore
crossover of diagnoses are a strong possibility. Nasal tissue
biopsy specimens from patients with AERD have shown
infiltration of eosinophils and degranulated mast cells.
AERD is an acquired disorder and aspirin hypersensitivity
can occur in patients who already have chronic or allergic
rhinitis and asthma [30]. The link between AERD and pre-
ceding allergic rhinitis has been suggested [32] and a sig-
nificant number of patients who develop AERD report
preceding symptomatic inhalant allergy [33] but a defini-
tive link remains elusive.
The evidence presented here supports that from a smaller
study of 51 patients from the Mayo clinic in 1994 [34], with
our reported prevalence of both asthma and aspirin sensi-
tivity of 58.8 and 29.0% in the AFRS cohort comparable
with their results of 54 and 27% respectively. A much
smaller Malaysian study reported a prevalence of asthma
and aspirin sensitivity as 37.5 and 25% respectively [35].
Our study is the largest to consider a spectrum of CRS dis-
orders as well aspirin sensitivity and asthma diagnoses.
AERD has been found to affect 0.3–2.5% of the general
population [31], a similar figure to the number of
participants who reported aspirin sensitivity amongst our
control and CRSsNPs groups (3 and 4.2% respectively).
This increased prevalence of aspirin sensitivity com-
bined with typically more aggressive inflammatory dis-
ease amongst those with AFRS may therefore reflect a
more complex or separate pathophysiological process
leading to its development [36].
Generalisability
Phenotypes of CRS with nasal polyps were associated
with an increased prevalence of aspirin sensitivity and
inhalant allergies, and therefore we hypothesise that,
clinically, this consideration may be helpful in the early
identification of patients who are more likely to suffer
from combined airway disease, both in primary and sec-
ondary care. The diagnosis of concurrent AR should also
be considered in all patients with CRS, and focused his-
tory taking should alert clinicians to the need for formal
allergy testing.
Treatment of rhinitis is thought to reduce asthma sever-
ity, so prompt treatment has an impact on both upper and
lower respiratory tract symptoms [37]. Patients themselves
report experiencing upper and lower respiratory symp-
toms which exacerbate each other. Care, however, is nor-
mally very divided between ENT and Respiratory medicine
with separate clinic teams for upper and lower respiratory
symptoms. In the UK, dedicated allergists are still only few
in number, and many patients with allergies will never
consult directly with an allergist. Patients report diffi-
culty in accessing care which takes both upper and
lower respiratory symptoms into account, and this
should be considered, with combined clinics or close
working relationships likely to improve quality and effi-
ciency of care [38]. Patients with asthma and/or aller-
gies have been found to be more likely to experience
delayed surgical intervention, and delayed surgical
intervention itself has been found to lead to less im-
provement in symptoms than early surgery [39]. Pa-
tients with asthma and aspirin or inhalant allergies may
therefore benefit from more aggressive treatment, in-
cluding timelier referral to specialist services and a
united approach from the clinicians involved.
Patients with AERD are more likely to suffer from aller-
gies in general [8], and it may be important to consider
testing for such allergies more comprehensively. Desensi-
tisation might be considered in patients with severe
Table 5 Frequency of participants with self-reported “confirmed” inhalant allergy and asthma
Group Frequency Percentage (of asthmatics in group) Percentage of whole group OR (95% CI) (whole group) OR (95% CI) (asthmatics)
Controls 8 28.9 3.6
CRSsNPs 42 27 7.6 2.19 (1.01,4.74) 0.98 (0.38,2.53)
CRSwNPs 130 37 20.1 6.71 (3.22,13.94) 1.32 (0.54,3.23)
AFRS 13 33 28.9 10.82 (4.16,28.13) 1.14 (0.37,3.47)
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aspirin or inhaled allergies. The current diagnostic criteria
for AFRS [4] do not take aspirin sensitivity into account,
but our results suggest that as aspirin sensitivity occurs in
40% of patients with AFRS, consideration should be given
to including it amongst the minor criteria along with
asthma, Charcot-Leyden crystals and peripheral eosino-
philia. Patients with both asthma and CRSwNPs may also
derive benefit from leukotriene receptor antagonists and
may be as beneficial as INCS [40].
Conclusion
The prevalence of asthma and allergy in CRS varies by phe-
noytype with CRSwNPs and AFRS having a stronger associ-
ation with both. Aspirin exacerbated respiratory disease has
a large overlap with allergic fungal rhinosinusitis suggesting
some common pathophysiology. These comorbidities are
significantly more prevalent than in non-CRS controls and
strengthen the need for a combined airways approach to in-
flammatory respiratory tract disease, with particular atten-
tion to assessment of allergy status. Large-scale studies with
standardised objective assessment of allergy status would
help to unravel any shared pathophysiology between these
diseases and could guide more efficient management. Lon-
gitudinal studies to look at the natural history of CRS may
also to understand the role of allergy and aspirin sensitivity
in relation to the pathophysiology.
Acknowledgements
The CRES group of otorhinolaryngologists who recruited patients to the study.
Jane Woods, Research Nurse at the James Paget University Hospital for her
dedication to the study.
On behalf of the CRES group:
Chief Investigator: Prof Carl Philpott, Professor of Rhinology & Olfactology at
University of East Anglia and Honorary Consultant ENT Surgeon, James Paget
University Hospital.
Miss Sally Erskine1, Prof Carl Philpott1*§, Dr. Allan Clark*, Prof Claire Hopkins2,
Mr. Alasdair Robertson4, Mr. Shahzada Ahmed6, Mr. Naveed Kara12, Mr. Sean
Carrie11, Mr. Vishnu Sunkaraneni20, Prof Jaydip Ray17, Mr. Shahram Anari7,
Mr. Paul Jervis10, Miss Jaan Panesaar18, Mr. Amir Farboud5, Prof Nirmal
Kumar3, Mr. Russell Cathcart8, Mr. Robert Almeyda14, Prof Hisham Khalil9, Mr.
Peter Prinsley13, Mr. Nicolas Mansell15, Mr. Mahmoud Salam16, Mr. Jonathan
Hobson19, Ms. Jane Woods1, Dr. Emma Coombes*.
1James Paget University Hospital NHS Foundation Trust, Gorleston, 2Guys &
St Thomas’ Hospital, London, 3Wrightington, Wigan & Leigh NHS Foundation
Trust, 4Southern General Hospital, Glasgow, 5Wrexham Maelor Hospital,
Wales, 6University Hospitals Birmingham, 7Heart of England NHS Foundation
Trust, Birmingham, 8Cumberland Infirmary, Carlisle, 9Derriford Hospital,
Plymouth, 10Northampton General Hospital, 11Freeman Hospital, Newcastle,
12Sunderland Royal Infirmary, 13Norfolk & Norwich University Hospital,
14Oxford University Hospitals, 15Royal Berkshire NHS Foundation Trust,
Reading, 16The Ipswich Hospital, 17Sheffield Teaching Hospitals, 18Luton &
Dunstable Hospital, 19Warrington and Halton Hospitals NHS Foundation
Trust, 20Royal Surrey County Hospital, Guildford, *Norwich Medical School,
University of East Anglia, Norfolk NR4 7TJ, United Kingdom, §Spire Norwich
Hospital.
NIHR portfolio ID: 12926; Funding: The Anthony Long Trust, the Bernice
Bibby Trust.
Funding
The study was funded by the Anthony Long Trust (postage costs) and the
Bernice Bibby Trust (research nurse time).
Authors’ contributions
According to the ICMJE authorship criteria: CP, SE, CH, NKumar, SA, NKara, SS,
and AC: Substantial contributions to conception and design of, or acquisition
of data or analysis and interpretation of data. CP, SE, CH, NKumar, SA, NKara, SS,
and AW: Drafting the article or revising it critically for important intellectual
content. CP, SE, CH, SA, NKara, SS, AC, and AW: final approval of the version to
be published. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The CRES was approved by the Oxford C Research Ethics Committee (Ref:
07/H0606/100), sponsored by the University of East Anglia (UEA).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1James Paget University Hospital NHS Foundation Trust, Gorleston, UK.
2Rhinology and Olfactology, University of East Anglia, Norwich, UK. 3Guys
and St Thomas’ Hospital, London, UK. 4Wrightington, Wigan and Leigh NHS
Foundation Trust, Wigan, UK. 5Heart of England NHS Foundation Trust,
Birmingham, UK. 6Sunderland Royal Infirmary, Sunderland, UK. 7Royal Surrey
County Hospital, Guildford, UK. 8Sheffield Teaching Hospitals, Sheffield, UK.
9Norwich Medical School, University of East Anglia, Norfolk NR4 7TJ, UK.
Received: 23 February 2018 Accepted: 8 June 2018
References
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N,
Cervin A, Douglas R, Gevaert P, et al: European position paper on
rhinosinusitis and nasal polyps 2012. Rhinol Suppl 2012:3 p preceding table
of contents, 1–298.
2. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A,
Bousquet PJ, Brozek G, Bruno A, Dahlén SE, et al. Chronic rhinosinusitis in
Europe – an underestimated disease. A GA2LEN study. Allergy. 2011;66:
1216–23.
3. Safirstein BH. ALlergic bronchopulmonary aspergillosis with obstruction of
the upper respiratory tract. Chest. 1976;70:788–90.
4. Bent JP 3rd, Kuhn FA. Diagnosis of allergic fungal sinusitis. Otolaryngol Head
Neck Surg. 1994;111:580–8.
5. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin
sensitivity and asthma. J Allergy Clin Immunol. 2006;118:773–86.
6. Widal M, Abrami P, Lermeyez J. Anaphylaxie et idiosyncrasie. Presse Med.
1922;30:189–92.
7. Samter M, Beers RF Jr. Concerning the nature of intolerance to aspirin. J
Allergy. 1967;40:281–93.
8. Garcia Cruz ML, Jimenez-Chobillon MA, Teran LM. Rhinosinusitis and aspirin-
exacerbated respiratory disease. J Allergy. 2012;2012:8.
9. Emanuel IA, Shah SB. Chronic rhinosinusitis: allergy and sinus computed
tomography relationships. Otolaryngol Head Neck Surg. 2000;123:687–91.
10. Gutman M, Torres A, Keen KJ, Houser SM. Prevalence of allergy in patients
with chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130:545–52.
11. Houser SM, Keen KJ. The role of allergy and smoking in chronic
rhinosinusitis and polyposis. Laryngoscope. 2008;118:1521–7.
12. Leo G, Piacentini E, Incorvaia C, Consonni D, Frati F. Chronic rhinosinusitis
and allergy. Pediatr Allergy Immunol. 2007;18(Suppl 18):19–21.
13. Staikuniene J, Vaitkus S, Japertiene LM, Ryskiene S. Association of chronic
rhinosinusitis with nasal polyps and asthma: clinical and radiological features,
allergy and inflammation markers. Medicina (Kaunas). 2008;44:257–65.
14. Bakhshaee M, Majidi MR, Gharavi V, Alavizadeh FS, Movahed R, Asnaashari P,
Asnaashari AM. Asthma in rhinosinusitis: a survey from Iran. Iran J
Otorhinolaryngol. 2016;28:275–80.
Philpott et al. Respiratory Research  (2018) 19:129 Page 8 of 9
15. Benninger MS, Sindwani R, Holy CE, Hopkins C. Impact of medically
recalcitrant chronic rhinosinusitis on incidence of asthma. Int Forum Allergy
Rhinol. 2016;6:124–9.
16. Chapurin N, Pynnonen MA, Roberts R, Schulz K, Shin JJ, Witsell DL, Parham
K, Langman A, Carpenter D, Vambutas A, et al. CHEER National Study of
chronic rhinosinusitis practice patterns. Otolaryngol Head Neck Surg. 2017;
https://doi.org/10.1177/0194599817691476.
17. Chung SD, Chen PY, Lin HC, Hung SH. Comorbidity profile of chronic
rhinosinusitis: a population-based study. Laryngoscope. 2014;124:
1536–41.
18. Frendo M, Hakansson K, Schwer S, Rix I, Ravn AT, Backer V, von Buchwald C.
Asthma in ear, nose, and throat primary care patients with chronic
rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2016;30:67–71.
19. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M,
Forsberg B, Gunnbjornsdottir M, Minov J, et al. Asthma in adults and its
association with chronic rhinosinusitis: the GA2LEN survey in Europe.
Allergy. 2012;67:91–8.
20. Kariyawasam HH, Rotiroti G. Allergic rhinitis, chronic rhinosinusitis and
asthma: unravelling a complex relationship. Curr Opin Otolaryngol Head
Neck Surg. 2013;21:79–86.
21. Yoshimura K, Kawata R, Haruna S, Moriyama H, Hirakawa K, Fujieda S,
Masuyama K, Takenaka H. Clinical epidemiological study of 553 patients
with chronic rhinosinusitis in Japan. Allergol Int. 2011;60:491–6.
22. Chen YT, Chien CY, Tai SY, Huang CM, Lee CT. Asthma associated with
chronic rhinosinusitis: a population-based study. Int Forum Allergy Rhinol.
2016;6:1284–93.
23. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop G, World
Health O. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol.
2001;108:S147–334.
24. Asano T, Kanemitsu Y, Takemura M, Yokota M, Fukumitsu K, Takeda N,
Ichikawa H, Uemura T, Takakuwa O, Ohkubo H, et al. Serum Periostin as a
biomarker for comorbid chronic rhinosinusitis in patients with asthma. Ann
Am Thorac Soc. 2017;
25. Hopkins C, Andrews P, Holy CE. Does time to endoscopic sinus surgery
impact outcomes in chronic rhinosinusitis? Retrospective analysis using the
UK clinical practice research data. Rhinology. 2015;53:18–24.
26. Philpott C, Erskine S, Hopkins C, Coombes E, Kara N, Sunkareneni V, Anari S,
Salam M, Farboud A, Clark A, Group C. A case-control study of medical,
psychological and socio-economic factors influencing the severity of
chronic rhinosinusitis. Rhinology. 2016;54:134–40.
27. Philpott CM, Javer AR, Clark A. Allergic fungal rhinosinusitis - a new staging
system. Rhinology. 2011;49:318–23.
28. National Guideline C. Allergic Rhinitis and its Impact on Asthma (ARIA) 2010
revision. Rockville: Agency for Healthcare Research and Quality (AHRQ);
2010.
29. Muittari A. Correlation of RAST and provocation tests for diagnosing allergic
asthma and rhinitis. Ann Allergy. 1978;40:406–8.
30. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced
asthma. AIANE investigators. European network on aspirin-induced asthma.
Eur Respir J. 2000;16:432–6.
31. Graefe H, Roebke C, Schäfer D, Meyer JE. Aspirin Sensitivity and Chronic
Rhinosinusitis with Polyps: A Fatal Combination. J Allergy. 2012;2012:10.
32. Schapowal AG, Simon HU, Schmitz-Schumann M. Phenomenology,
pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis.
Acta Otorhinolaryngol Belg. 1995;49:235–50.
33. Kowalski ML. Aspirin-sensitive rhinosinusitis and asthma. Clin Allergy
Immunol. 2007;19:147–75.
34. Cody DT 2nd, Neel HB 3rd, Ferreiro JA, Roberts GD. Allergic fungal sinusitis:
the Mayo Clinic experience. Laryngoscope. 1994;104:1074–9.
35. Goh BS, Gendeh BS, Rose IM, Pit S, Samad SA. Prevalence of allergic fungal
sinusitis in refractory chronic rhinosinusitis in adult Malaysians. Otolaryngol
Head Neck Surg. 2005;133:27–31.
36. Kowalski ML. Rhinosinusitis and nasal polyposis in aspirin sensitive and
aspirin tolerant patients: are they different? Thorax. 2000;55:S84–6.
37. Crystal-Peters JNC, Crown WH, Torres A. Treating allergic rhinitis in
patients with comorbid asthma: the risk of asthma-related
hospitalizations and emergency department visits. J Allergy Clin
Immunol. 2002;109:57–62.
38. Erskine SE, Notley C, Wilson AM, Philpott CM. Managing chronic
rhinosinusitis and respiratory disease: a qualitative study of triggers and
interactions. J Asthma. 2014;0:1–6.
39. Hopkins C, Rimmer J, Lund VJ. Does time to endoscopic sinus surgery
impact outcomes in chronic rhinosinusitis? Prospective findings from the
National Comparative Audit of surgery for nasal polyposis and chronic
rhinosinusitis. Rhinology. 2015;53:10–7.
40. Wentzel JL, Soler ZM, DeYoung K, Nguyen SA, Lohia S, Schlosser RJ.
Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic
review. Am J Rhinol Allergy. 2013;27:482–9.
Philpott et al. Respiratory Research  (2018) 19:129 Page 9 of 9
